Literature DB >> 25563884

Surgical Indications and Procedures for Resection of Hepatic Malignancies Confined to Segment VII.

Chetana Lim1, Takeaki Ishizawa, Akinori Miyata, Yoshihiro Mise, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Yasuhiko Sugawara, Norihiro Kokudo.   

Abstract

OBJECTIVE: To establish a strategy for surgical resection of hepatic malignancies confined to segment VII.
BACKGROUND: Various surgical procedures can be used to resect hepatic malignancies in segment VII, the deepest region of the liver, by open and/or laparoscopic approaches: nonanatomic wedge resection (WR), segmentectomy VII, right lateral sectionectomy (RLS), and right hepatectomy.
METHODS: WR and segmentectomy VII were applied as first-line surgical procedures for colorectal liver metastasis (CRLM) and hepatocellular carcinoma (HCC), respectively. RLS and right hepatectomy were indicated only when tumor infiltration to the proximal Glissonian sheath was suspected. Operative outcomes were evaluated in 200 consecutive patients who underwent hepatic resection for HCC (n = 120) or CRLM (n = 80).
RESULTS: WR, segmentectomy VII, RLS, and right hepatectomy were performed in 104 (52.0%), 57 (28.5%), 22 (11.0%), and 17 (8.5%) patients, respectively. Local hepatectomy (WR and segmentectomy VII) led to shorter operation times and lower blood loss volumes than did extensive hepatectomy (RLS and right hepatectomy). Thoracotomy was performed in half of the WR and two-thirds of the segmentectomy VII procedures. The availability of a laparoscopic approach was 40% (8 patients) after its application in October 2012.
CONCLUSIONS: Even for hepatic malignancies located in segment VII, WR and segmentectomy should be prioritized over extensive hepatectomy to preserve the postoperative functional hepatic volume. Full mobilization of the right liver and a good surgical field provided by a large thoracoabdominal or abdominal incision or a laparoscopic approach are key factors for safe performance of deep hepatic transection.

Entities:  

Mesh:

Year:  2016        PMID: 25563884     DOI: 10.1097/SLA.0000000000001118

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  6 in total

1.  Laparoscopic liver resection of hepatocellular carcinoma located in segments 7 or 8.

Authors:  Hanisah Guro; Jai Young Cho; Ho-Seong Han; Yoo-Seok Yoon; YoungRok Choi; Jae Seong Jang; Seong Uk Kwon; Sungho Kim; Jang Kyu Choi
Journal:  Surg Endosc       Date:  2017-07-20       Impact factor: 4.584

2.  Use of intercostal trocars for laparoscopic resection of subphrenic hepatic tumors.

Authors:  Hirofumi Ichida; Takeaki Ishizawa; Masayuki Tanaka; Muga Terasawa; Genki Watanabe; Yoshinori Takeda; Ryota Matsuki; Masaru Matsumura; Taigo Hata; Yoshinori Mise; Yosuke Inoue; Yu Takahashi; Akio Saiura
Journal:  Surg Endosc       Date:  2016-07-21       Impact factor: 4.584

Review 3.  Systematic review of the feasibility and future of laparoscopic liver resection for difficult lesions.

Authors:  Kenichiro Araki; Norio Kubo; Akira Watanabe; Hiroyuki Kuwano; Ken Shirabe
Journal:  Surg Today       Date:  2017-11-13       Impact factor: 2.549

4.  Laparoscopic liver resection for malignancies confined to Couinaud's segment VII in the robotic surgery era.

Authors:  Maurizio Zizzo; Lara Ugoletti; Carolina Castro Ruiz; Magda Zanelli; Loredana De Marco; Claudio Pedrazzoli; Valerio Annessi
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

5.  Reply to: The letter to the editor "Laparoscopic liver resection for malignancies confined to Couinaud's segment VII in the robotic surgery era" by Zizzo et al.

Authors:  Ning-Yuan Wen; Yong-Gang Wei; Fei Liu; Hai-Li Zhang
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

6.  Laparoscopic versus open resections in the posterosuperior liver segments within an enhanced recovery programme (ORANGE Segments): study protocol for a multicentre randomised controlled trial.

Authors:  Christoph Kuemmerli; Robert S Fichtinger; Alma Moekotte; Luca A Aldrighetti; Somaiah Aroori; Marc G H Besselink; Mathieu D'Hondt; Rafael Díaz-Nieto; Bjørn Edwin; Mikhail Efanov; Giuseppe M Ettorre; Krishna V Menon; Aali J Sheen; Zahir Soonawalla; Robert Sutcliffe; Roberto I Troisi; Steven A White; Lloyd Brandts; Gerard J P van Breukelen; Jasper Sijberden; Siân A Pugh; Zina Eminton; John N Primrose; Ronald van Dam; Mohammed Abu Hilal
Journal:  Trials       Date:  2022-03-09       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.